Literature DB >> 33641863

The Role of Megakaryocytes in Myelofibrosis.

Johanna Melo-Cardenas1, Anna Rita Migliaccio2, John D Crispino3.   

Abstract

Megakaryocytes give rise to platelets, which have a wide variety of functions in coagulation, immune response, inflammation, and tissue repair. Dysregulation of megakaryocytes is a key feature of in the myeloproliferative neoplasms, especially myelofibrosis. Megakaryocytes are among the main drivers of myelofibrosis by promoting myeloproliferation and bone marrow fibrosis. In vivo targeting of megakaryocytes by genetic and pharmacologic approaches ameliorates the disease, underscoring the important role of megakaryocytes in myeloproliferative neoplasms. Here we review the current knowledge of the function of megakaryocytes in the JAK2, CALR, and MPL-mutant myeloproliferative neoplasms.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  JAK/STAT; Megakaryocyte; Myeloproliferative neoplasms

Mesh:

Substances:

Year:  2021        PMID: 33641863      PMCID: PMC7921544          DOI: 10.1016/j.hoc.2020.11.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  129 in total

1.  Inflammation-Induced Emergency Megakaryopoiesis Driven by Hematopoietic Stem Cell-like Megakaryocyte Progenitors.

Authors:  Simon Haas; Jenny Hansson; Daniel Klimmeck; Dirk Loeffler; Lars Velten; Hannah Uckelmann; Stephan Wurzer; Áine M Prendergast; Alexandra Schnell; Klaus Hexel; Rachel Santarella-Mellwig; Sandra Blaszkiewicz; Andrea Kuck; Hartmut Geiger; Michael D Milsom; Lars M Steinmetz; Timm Schroeder; Andreas Trumpp; Jeroen Krijgsveld; Marieke A G Essers
Journal:  Cell Stem Cell       Date:  2015-08-20       Impact factor: 24.633

2.  Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.

Authors:  Olivier Mansier; Badr Kilani; Amélie V Guitart; Alexandre Guy; Virginie Gourdou-Latyszenok; Caroline Marty; Marie Parrens; Isabelle Plo; William Vainchenker; Chloé James
Journal:  Blood       Date:  2019-12-26       Impact factor: 22.113

3.  Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis.

Authors:  Sara C Meyer; Matthew D Keller; Brittany A Woods; Lindsay M LaFave; Lennart Bastian; Maria Kleppe; Neha Bhagwat; Sachie Marubayashi; Ross L Levine
Journal:  Blood       Date:  2014-08-12       Impact factor: 22.113

4.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

5.  Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis.

Authors:  Rita Campanelli; Vittorio Rosti; Laura Villani; Marta Castagno; Enza Moretti; Elisa Bonetti; Gaetano Bergamaschi; Alessandra Balduini; Giovanni Barosi; Margherita Massa
Journal:  Cytokine       Date:  2010-08-30       Impact factor: 3.861

6.  CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis.

Authors:  Mirko Moreno Zaldivar; Katrin Pauels; Philipp von Hundelshausen; Marie-Luise Berres; Petra Schmitz; Jörg Bornemann; M Anna Kowalska; Nikolaus Gassler; Konrad L Streetz; Ralf Weiskirchen; Christian Trautwein; Christian Weber; Hermann E Wasmuth
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

7.  Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

Authors:  Ayalew Tefferi; Paola Guglielmelli; Dirk R Larson; Christy Finke; Emnet A Wassie; Lisa Pieri; Naseema Gangat; Rajmonda Fjerza; Alem A Belachew; Terra L Lasho; Rhett P Ketterling; Curtis A Hanson; Alessandro Rambaldi; Guido Finazzi; Juergen Thiele; Tiziano Barbui; Animesh Pardanani; Alessandro M Vannucchi
Journal:  Blood       Date:  2014-07-18       Impact factor: 22.113

8.  A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells.

Authors:  Xiaoli Wang; David Haylock; Cing Siang Hu; Wioleta Kowalczyk; Tianbo Jiang; Jiajing Qiu; Goar Mosoyan; Wu He; Netonia Marshall; John Mascarenhas; Anna Tarasova; Joshua Brody; David Winkler; Ronald Hoffman
Journal:  Blood       Date:  2016-04-25       Impact factor: 22.113

9.  MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Authors:  Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross L Levine
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

10.  Somatic mutations and cell identity linked by Genotyping of Transcriptomes.

Authors:  Anna S Nam; Kyu-Tae Kim; Ronan Chaligne; Franco Izzo; Chelston Ang; Justin Taylor; Robert M Myers; Ghaith Abu-Zeinah; Ryan Brand; Nathaniel D Omans; Alicia Alonso; Caroline Sheridan; Marisa Mariani; Xiaoguang Dai; Eoghan Harrington; Alessandro Pastore; Juan R Cubillos-Ruiz; Wayne Tam; Ronald Hoffman; Raul Rabadan; Joseph M Scandura; Omar Abdel-Wahab; Peter Smibert; Dan A Landau
Journal:  Nature       Date:  2019-07-03       Impact factor: 49.962

View more
  4 in total

1.  [Establishment of a platelet production model by bone marrow cavity transplantation of mouse primary megakaryocytes].

Authors:  B M Huang; X Y Chen; M J Xia; L Zheng; C C Liu; J J Zhao; P Su; H T Wang; J X Zhou
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-04-14

Review 2.  JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation.

Authors:  Garima Pandey; Andrew T Kuykendall; Gary W Reuther
Journal:  Blood Cancer J       Date:  2022-01-26       Impact factor: 11.037

3.  G6b-B regulates an essential step in megakaryocyte maturation.

Authors:  Isabelle C Becker; Zoltan Nagy; Georgi Manukjan; Melanie Haffner-Luntzer; Maximilian Englert; Tobias Heib; Timo Vögtle; Carina Gross; Richa Bharti; Sascha Dietrich; Kristina Mott; Johannes Heck; Sebastian Stegmaier; Anke Baranowsky; Thorsten Schinke; Nicolas Schlegel; Tobias Heckel; David Stegner; Irina Pleines; Anita Ignatius; Harald Schulze; Bernhard Nieswandt
Journal:  Blood Adv       Date:  2022-05-24

4.  Systems biology and machine learning approaches identify drug targets in diabetic nephropathy.

Authors:  Maryam Abedi; Hamid Reza Marateb; Mohammad Reza Mohebian; Seyed Hamid Aghaee-Bakhtiari; Seyed Mahdi Nassiri; Yousof Gheisari
Journal:  Sci Rep       Date:  2021-12-06       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.